Adimab will transfer its platform to Takeda Pharmaceuticals for the discovery and optimization of antibody and non-antibody-based protein therapeutics.
The two companies have been collaborating since 2016 and this agreement to transfer the platform serves as an expansion to the original agreement.
According to a statement made by Tillman Gerngross, CEO of Admiab, the company has initiated approximately 25 programs per year internally that involve discovery, optimization, and bispecifics, all of which use its CD3 antibodies.
Through the transfer, Takeda will have license at multiple research sites for discovery and optimization of modalities across various therapeutic areas.
The Adimab Platform enables user access to the internal capability to engineer different complex molecules in its pipeline diversification strategy in biologics and modalities for use without any target restrictions. Additionally, the agreement will grant Takeda access to human antibody libraries.
Robert Mabry, head of global biologics research at Takeda said in a statement that Adimab’s antibody discovery platform will help Takeda diversify its pipeline beyond small molecules and expand its modalities for monoclonal antibody (mAb) therapeutics along with other mechanisms of action enabled by antibody binders.
Takeda will also receive continued improvements to the Adimab Platform, including access to new antibody libraries.